Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways

International Journal of Molecular Sciences

Volumn 13, Issue 1, 2012, Pages 828-839

  Liu, Dawo ^a   Liu, Juanjuan ^a   Lin, Bei ^a   Liu, Shuice ^a   Hou, Rui ^a   Hao, Yingying ^a   Liu, Qing ^a   Zhang, Shulan ^a   Iwamori, Masao ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Cell cycle; Cyclin; Cyclin dependent kinase inhibitors; Cyclin dependent kinases; Lewis(y) antigen

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CELL PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN LEWIS Y; PROTEIN P16; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTIBODY; BLOOD GROUP LEWIS SYSTEM; CHROMONE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLAVONOID; FUCOSYLTRANSFERASE; LEWIS Y ANTIGEN; MORPHOLINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BLOOD GROUP LEWIS SYSTEM; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES; CELL LINE, TUMOR; CHROMONES; CYCLIN A; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLAVONOIDS; FUCOSYLTRANSFERASES; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MORPHOLINES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84863011064     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13010828     Document Type: Article

References (27)

1. Hao, Y.Y.; Lin, B.; Zhang, Y.H.; Li, F.F.; Diao, B.; Zhang, S.L. α1,2-Fucosyltransferase gene translection in fluences on biological behavior of ovarian carcinoma-derived RMG-1 cells (in Chinese). Fen Zi Xi Bao Sheng Wu Xue Bao 2008, 41, 435-442.
2. Sherr, C.J. Mammalian G1 cyclins and cell cycle progression. Proc. Assoc. Am. Physicians 1995, 107, 181-186.
3. Ruas, M.; Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1998, 1378, F115-F177.
4. Sherr, C.J. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 2000, 60, 3689-3695.
5. Liu, J.J.; Lin, B.; Hao, Y.Y.; Li, F.F.; Liu, D.W.; Qi, Y.; Zhu, L.C.; Zhang, S.L.; Iwamori, M. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol. Rep. 2010, 23, 833-841.
6. Liu, D.W.; Liu, J.J.; Wang, C.Z.; Lin, B.; Liu, Q.; Hao, Y.Y.; Zhang, S.L.; Iwamori, M. The Stimulation of IGF-1R Expression by Lewis(y) Antigen Provides a Powerful Development Mechanism of Epithelial Ovarian Carcinoma. Int. J. Mol. Sci. 2011, 12, 6781-6795.
7. Yan, L.M.; Lin, B.; Zhu, L.C.; Hao, Y.Y.; Qi, Y.; Wang, C.Z.; Gao, S.; Liu, S.C.; Zhang, S.L.; Iwamori, M. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5 beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie 2010, 92, 852-857.
8. Liu, J.J.; Lin, B.; Hao, Y.Y.; Qi, Y.; Zhu, L.C.; Li, F.F.; Liu, D.W.; Cong, J.P.; Zhang, S.L.; Iwamori, M. Lewis(y) antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cell through the PI3K/Akt signaling pathway. J. Exp. Clin. Cancer Res. 2009, 28, 154:1-154:12.
9. Coolican, S.A.; Samuel, D.S.; Ewton, D.Z.; McWade, F.J.; Florini, J.R. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem. 1997, 272, 6653-6662.
10. Meloche, S.; Pouysségur, J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26, 3227-3239.
11. Girnita, L.; Shenoy, S.K.; Sehat, B.; Vasilcanu, R.; Vasilcanu, D.; Girnita, A.; Lefkowitz, RJ.; Larsson, O. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J. Biol. Chem. 2007, 282, 11329-11338.
12. Halevy, O.; Cantley, L.C. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells. Exp. Cell Res. 2004, 297, 224-234.
13. Rommel, C.; Bodine, S.C.; Clarke, B.A.; Rossman, R.; Nunez, L.; Stitt, T.N.; Yancopoulos, G.D.; Glass, DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3, 1009-1013.
14. Kornasio, R.; Riederer, I.; Butler-Browne, G.; Mouly, V.; Uni, Z.; Halevy, O. β-hydroxy-β-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways. Biochim. Biophys. Acta 2009, 1793, 755-763.
15. Yang, T.Y.; Chang, G.C.; Chen, K.C.; Hung, H.W.; Hsu, K.H.; Sheu, G.T.; Hsu, S.L. Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur. J. Pharmacol. 2011, 663, 17-26.
16. Chen, J.; Zeng, J.; Xin, M.; Huang, W.; Chen, X. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm. Metab. Res. 2011, 43, 681-686.
17. Tocchi, A.; Mazzoni, G.; Fornasari, V.; Miccini, M.; Daddi, G.; Tagliacozzo, S. Preservation of the inferior mesenteric artery in colorectal resection for complicated diverticular disease. Am. J. Surg. 2001, 182, 162-167.
18. Koroleva, O.A.; Tomlinson, M.; Parinyapong, P.; Sakvarelidze, L.; Leader, D.; Shaw, P.; Doonan, J.H. CycD1, a putative G1 cyclin from Antirrhinum majus, accelerates the cell cycle in cultured tobacco BY-2 cells by enhancing both G1/S entry and progression through S and G2 phases. Plant Cell 2004, 16, 2364-2379.
19. Ohtsubo, M.; Theodoras, A.M.; Schumacher, J.; Roberts, J.M.; Pagano, M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 1995, 15, 2612-2624
20. Lee, M.H.; Yang, H.Y. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev. 2003, 22, 435-449.
21. Vidal, A.; Koff, A. Cell-cyclin inhibitors: Three families united by common cause. Gene 2000, 247, 1-15.
22. Polyak, K.; Lee, M.H.; Erdjurment-Bromage, H.; Koff, A.; Roberts, J.M.; Tempst, P.; Massagué, J. Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78, 59-66.
23. Abbas, T.; Dutta, A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9, 400-414.
24. Kashima, H.; Shiozawa, T.; Miyamoto, T.; Suzuki, A.; Uchikawa, J.; Kurai, M.; Konishi, I. Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: Involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr. Relat. Cancer 2009, 16, 113-122.
25. Burch, L.R.; Scott, M.; Pohler, E.; Meek, D.; Hupp, T. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1. J. Mol. Biol. 2004, 337, 115-128.
26. Polyak, K.; Kato, J.Y.; Solomon, M.J.; Sherr, C.J.; Massague, J.; Roberts, J.M.; Koff, A. p27Kip1, a cyclin-CDK inhibitor; links transforming growth factor-b and contact inhibiton to cell cycle arrest. Genes Dev. 1994, 8, 9-22.
27. Toyoshima, H.; Hunter, T. P27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994, 78, 67-74.